EGFR and neoplasm: In breast cancer cells, ES-072 (an EGFR inhibitor) increases the phosphorylation levels at S279 and S283 sites of the PD-L1 protein intracellular segment through the EGFR-GSK3α pathway, promoting the interaction between PD-L1 and ARIH1, thereby regulating PD-L1 degradation through the proteasome and promoting anti-tumor immunity [282].